SRC and breast cancer: It has been shown that SRC activation confers resistance to the HER2/EGFR tyrosine kinase inhibitor lapatinib45, while knockdown of SRC was found to sensitize response to PI3Kα inhibitor alpelisib in ER+ BC cells46.